• Home
  • »
  • About Alexion

About Alexion

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with severe and life-threatening rare diseases. Patients with these devastating diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know there is a significant unmet medical need, and that people's lives depend on our work.

Alexion is the global leader in complement inhibition. We developed and market Soliris® (eculizumab), the world’s first and only approved terminal complement inhibitor, as a treatment for patients suffering from paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uremic syndrome (atypical HUS), two severe and life-threatening ultra-rare diseases. Soliris is currently approved in nearly 50 countries for the treatment of PNH and in nearly 40 countries for the treatment of atypical HUS. Alexion is also committed to investing in research and development focused on novel therapies with life-transforming potential.

Alexion’s work has been recognized many times, including with the prestigious Prix Galien Award for the medical breakthrough of Soliris, both in the U.S. (2008 Best Biotechnology Product) and in France (2009 Best Drug for a Rare Disease). Alexion has also been ranked second in Forbes’ list of the World’s Most Innovative Companies three years in a row (2012 - 2014).

Alexion was founded in 1992 and today has operations to serve patients with severe and life-threatening rare diseases in nearly 50 countries. Learn more about our company history.

For more information about Alexion globally, visit www.alexion.com.